Literature DB >> 24928715

Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC?

Esther Diana Rossi1, Tommaso Bizzarro, Guido Fadda, Luigi Maria Larocca, Fernando Schmitt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24928715     DOI： 10.1007/s00428-014-1607-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  5 in total

1.  Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience.

Authors:  Esther Diana Rossi; Maurizio Martini; Sara Capodimonti; Tonia Cenci; Patrizia Straccia; Basilio Angrisani; Costantino Ricci; Paola Lanza; Celestino Pio Lombardi; Alfredo Pontecorvi; Luigi Maria Larocca; Guido Fadda
Journal:  Cancer Cytopathol       Date:  2014-03-17       Impact factor: 5.284

2.  Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.

Authors:  Alexander Finkelstein; Gillian H Levy; Pei Hui; Avinash Prasad; Renu Virk; David C Chhieng; Tobias Carling; Sanziana A Roman; Julie A Sosa; Robert Udelsman; Constantine G Theoharis; Manju L Prasad
Journal:  Histopathology       Date:  2012-02-15       Impact factor: 5.087

3.  Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study.

Authors:  Renu K Virk; Constantine G A Theoharis; Avinash Prasad; David Chhieng; Manju L Prasad
Journal:  Virchows Arch       Date:  2014-02-19       Impact factor: 4.064

4.  BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.

Authors:  Esther Diana Rossi; Maurizio Martini; Sara Capodimonti; Celestino Pio Lombardi; Alfredo Pontecorvi; Valerio Gaetano Vellone; Gian Franco Zannoni; Luigi Maria Larocca; Guido Fadda
Journal:  Cancer Cytopathol       Date:  2012-11-28       Impact factor: 5.284

5.  Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.

Authors:  Arnaldur Hall; Kathrine Damm Meyle; Marina Krarup Lange; Martin Klima; May Sanderhoff; Christina Dahl; Cecilie Abildgaard; Katrine Thorup; Seyed Moein Moghimi; Per Bo Jensen; Jiri Bartek; Per Guldberg; Claus Christensen
Journal:  Oncotarget       Date:  2013-04
  5 in total
  2 in total

1.  The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation.

Authors:  Esther Diana Rossi; Tommaso Bizzarro; Sara Granja; Maurizio Martini; Sara Capodimonti; Emilia Luca; Guido Fadda; Celestino Pio Lombardi; Alfredo Pontecorvi; Luigi Maria Larocca; Fatima Baltazar; Fernando Schmitt
Journal:  Endocrine       Date:  2016-08-02       Impact factor: 3.633

Review 2.  Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples.

Authors:  Esther Diana Rossi; Maurizio Martini; Tommaso Bizzarro; Fernando Schmitt; Adhemar Longatto-Filho; Luigi Maria Larocca
Journal:  Oncotarget       Date:  2017-01-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.